Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
Vera E BukkemsH van HoveD RoelofsenJ J M FreriksenE W J van Ewijk-Beneken KolmerD M BurgerJ van DrongelenE M SvenssonR GreupinkA ColbersPublished in: Clinical pharmacokinetics (2022)
Substantially reduced maternal doravirine exposure was predicted during pregnancy, possibly resulting in impaired efficacy. Therapeutic drug and viral load monitoring are advised for pregnant women treated with doravirine. Considerable fetal doravirine exposure was predicted, highlighting the need for clinical fetal safety data.